{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T18:31:07Z","timestamp":1786991467756,"version":"build-2736575974"},"reference-count":13,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","japha.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Pharmacists Association"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.japh.2024.01.022","type":"journal-article","created":{"date-parts":[[2024,2,4]],"date-time":"2024-02-04T01:36:32Z","timestamp":1707010592000},"page":"102026","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Naloxone access in perinatal substance use disorder"],"prefix":"10.1016","volume":"64","author":[{"given":"Abigail C.","family":"Bechtol","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5291-5670","authenticated-orcid":false,"given":"Melinda","family":"Ramage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linas J.","family":"Krulikas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-4700-8880","authenticated-orcid":false,"given":"Kylie","family":"Futrell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8315-8908","authenticated-orcid":false,"given":"Olivia","family":"Caron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.japh.2024.01.022_bib2","doi-asserted-by":"crossref","first-page":"3079","DOI":"10.1111\/add.15959","article-title":"Duration of medication treatment for opioid-use disorder and risk of overdose among Medicaid enrollees in 11 states: a retrospective cohort study","volume":"117","author":"Burns","year":"2022","journal-title":"Addiction"},{"issue":"21","key":"10.1016\/j.japh.2024.01.022_bib4","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1001\/jama.2022.17045","article-title":"US trends in drug overdose mortality among pregnant and postpartum persons, 2017-2020","volume":"328","author":"Bruzelius","year":"2022","journal-title":"JAMA"},{"key":"10.1016\/j.japh.2024.01.022_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2019.06.038","article-title":"Impact of a community-based naloxone distribution program on opioid overdose death rates","volume":"204","author":"Naumann","year":"2019","journal-title":"Drug Alcohol Depend"},{"issue":"31","key":"10.1016\/j.japh.2024.01.022_bib9","doi-asserted-by":"crossref","first-page":"679","DOI":"10.15585\/mmwr.mm6831e1","article-title":"Vital signs: pharmacy-based naloxone dispensing - United States, 2012-2018","volume":"68","author":"Guy","year":"2019","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"6","key":"10.1016\/j.japh.2024.01.022_bib10","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1001\/jamainternmed.2019.0272","article-title":"Association between state laws facilitating pharmacy distribution of naloxone and risk of fatal overdose","volume":"179","author":"Abouk","year":"2019","journal-title":"JAMA Intern Med"},{"issue":"7","key":"10.1016\/j.japh.2024.01.022_bib12","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1093\/ajhp\/zxaa007","article-title":"Assessing the impact of clinical pharmacists on naloxone coprescribing in the primary care setting","volume":"77","author":"Watson","year":"2020","journal-title":"Am J Health Syst Pharm"},{"issue":"6","key":"10.1016\/j.japh.2024.01.022_bib13","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/j.japh.2019.07.012","article-title":"Evaluation of a pharmacist-led naloxone coprescribing program in primary care","volume":"59","author":"Cariveau","year":"2019","journal-title":"J\u00a0Am Pharm Assoc (2003)"},{"issue":"3","key":"10.1016\/j.japh.2024.01.022_bib14","first-page":"181","article-title":"Improving intranasal naloxone prescribing through EMR modification and automation","volume":"15","author":"Crusco","year":"2021","journal-title":"J\u00a0Addict Med"},{"issue":"5","key":"10.1016\/j.japh.2024.01.022_bib15","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1001\/jama.2019.7988","article-title":"Naloxone co-prescribing to patients receiving prescription opioids in the medicare part D program, United States, 2016-2017","volume":"322","author":"Jones","year":"2019","journal-title":"JAMA"},{"issue":"10","key":"10.1016\/j.japh.2024.01.022_bib16","doi-asserted-by":"crossref","first-page":"2952","DOI":"10.1007\/s11606-020-06577-5","article-title":"Individual and community factors associated with naloxone co-prescribing among long-term opioid patients: a retrospective analysis","volume":"36","author":"Stein","year":"2021","journal-title":"J\u00a0Gen Intern Med"},{"key":"10.1016\/j.japh.2024.01.022_bib17","doi-asserted-by":"crossref","first-page":"j1550","DOI":"10.1136\/bmj.j1550","article-title":"Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies","volume":"357","author":"Sordo","year":"2017","journal-title":"BMJ"},{"issue":"2","key":"10.1016\/j.japh.2024.01.022_bib18","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1176\/appi.ajp.2019.19060612","article-title":"Acute care, prescription opioid use, and overdose following discontinuation of long-term buprenorphine treatment for opioid use disorder","volume":"177","author":"Williams","year":"2020","journal-title":"Am J Psychiatry"},{"issue":"6","key":"10.1016\/j.japh.2024.01.022_bib19","first-page":"364","article-title":"Increasing naloxone prescribing in the emergency department through education and electronic medical record work-Aids","volume":"47","author":"Funke","year":"2021","journal-title":"Jt Comm J Qual Patient Saf"}],"container-title":["Journal of the American Pharmacists Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1544319124000293?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1544319124000293?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,7]],"date-time":"2025-01-07T21:06:21Z","timestamp":1736283981000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1544319124000293"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":13,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["S1544319124000293"],"URL":"https:\/\/doi.org\/10.1016\/j.japh.2024.01.022","relation":{},"ISSN":["1544-3191"],"issn-type":[{"value":"1544-3191","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Naloxone access in perinatal substance use disorder","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Pharmacists Association","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.japh.2024.01.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 American Pharmacists Association\u00ae. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102026"}}